Methods and processes of the CONSORT Group: example of an extension for trials assessing nonpharmacologic treatments - PubMed (original) (raw)
Methods and processes of the CONSORT Group: example of an extension for trials assessing nonpharmacologic treatments
Isabelle Boutron et al. Ann Intern Med. 2008.
Free article
Abstract
Background: The conduct of randomized, controlled trials of nonpharmacologic treatments presents specific challenges that are not adequately addressed in trial reports.
Objective: To develop an extension of the CONSORT (Consolidated Standards of Reporting Trials) Statement for trials of nonpharmacologic treatments.
Design: A consensus meeting was organized to develop an extension of the CONSORT Statement that addresses randomized trials of nonpharmacologic treatments. To prepare for the meeting, a survey was conducted to identify the specific issues for discussion.
Setting: Consensus meeting in Paris, France.
Participants: A total of 33 experts attended the meeting. The experts were methodologists (n = 17); surgeons (n = 6); editors (n = 5); and clinicians involved in rehabilitation (n = 1), psychotherapy (n = 2), education (n = 1), and implantable devices (n = 1).
Measurements: Experts indicated which of the 22 items on the CONSORT checklist should be modified or which additional items should be added specifically for nonpharmacologic treatments. During a 3-day consensus meeting, all items were discussed and additional methodological issues related to nonpharmacologic research were identified.
Results: The consensus was that 11 items on the CONSORT checklist needed some modifications for nonpharmacologic trials: item 1 (title and abstract), item 3 (participants), item 4 (interventions), item 7 (sample size), item 8 (randomization), item 11 (blinding), item 12 (statistical methods), item 13 (participant flow), item 15 (baseline data), item 20 (discussion: interpretation), and item 21 (generalizability). In addition, the meeting participants added 1 item related to implementation of the intervention.
Limitation: Evidence was not always available to support the inclusion of each checklist item.
Conclusion: The methods and processes used to develop this extension could be used for other reporting guidelines. The use of this extension to the CONSORT Statement should improve the quality of reporting randomized, controlled trials assessing nonpharmacologic treatments.
Similar articles
- Extending the CONSORT statement to randomized trials of nonpharmacologic treatment: explanation and elaboration.
Boutron I, Moher D, Altman DG, Schulz KF, Ravaud P; CONSORT Group. Boutron I, et al. Ann Intern Med. 2008 Feb 19;148(4):295-309. doi: 10.7326/0003-4819-148-4-200802190-00008. Ann Intern Med. 2008. PMID: 18283207 - CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A 2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts.
Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P; CONSORT NPT Group. Boutron I, et al. Ann Intern Med. 2017 Jul 4;167(1):40-47. doi: 10.7326/M17-0046. Epub 2017 Jun 20. Ann Intern Med. 2017. PMID: 28630973 - The REFLECT statement: methods and processes of creating reporting guidelines for randomized controlled trials for livestock and food safety by modifying the CONSORT statement.
O'Connor AM, Sargeant JM, Gardner IA, Dickson JS, Torrence ME; Consensus Meeting Participants; Dewey CE, Dohoo IR, Evans RB, Gray JT, Greiner M, Keefe G, Lefebvre SL, Morley PS, Ramirez A, Sischo W, Smith DR, Snedeker K, Sofos J, Ward MP, Wills R. O'Connor AM, et al. Zoonoses Public Health. 2010 Mar;57(2):95-104. doi: 10.1111/j.1863-2378.2009.01311.x. Epub 2010 Jan 12. Zoonoses Public Health. 2010. PMID: 20070653 - Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension.
Butcher NJ, Monsour A, Mew EJ, Chan AW, Moher D, Mayo-Wilson E, Terwee CB, Chee-A-Tow A, Baba A, Gavin F, Grimshaw JM, Kelly LE, Saeed L, Thabane L, Askie L, Smith M, Farid-Kapadia M, Williamson PR, Szatmari P, Tugwell P, Golub RM, Monga S, Vohra S, Marlin S, Ungar WJ, Offringa M. Butcher NJ, et al. JAMA. 2022 Dec 13;328(22):2252-2264. doi: 10.1001/jama.2022.21022. JAMA. 2022. PMID: 36511921 Review. - Reporting randomised trials of social and psychological interventions: the CONSORT-SPI 2018 Extension.
Montgomery P, Grant S, Mayo-Wilson E, Macdonald G, Michie S, Hopewell S, Moher D; CONSORT-SPI Group. Montgomery P, et al. Trials. 2018 Jul 31;19(1):407. doi: 10.1186/s13063-018-2733-1. Trials. 2018. PMID: 30060754 Free PMC article.
Cited by
- How far can we go? A 20-year meta-analysis of dental implant survival rates.
Kupka JR, König J, Al-Nawas B, Sagheb K, Schiegnitz E. Kupka JR, et al. Clin Oral Investig. 2024 Sep 21;28(10):541. doi: 10.1007/s00784-024-05929-3. Clin Oral Investig. 2024. PMID: 39305362 Free PMC article. - Prevention of malaria in pregnancy through health education intervention programs on insecticide-treated nets use: a systematic review.
Onyinyechi OM, Ismail S, Nashriq Mohd Nazan AI. Onyinyechi OM, et al. BMC Public Health. 2024 Mar 11;24(1):755. doi: 10.1186/s12889-024-17650-7. BMC Public Health. 2024. PMID: 38468243 Free PMC article. - Biofield Therapies: Guidelines for Reporting Clinical Trials.
Hammerschlag R, Sprengel M, Baldwin AL. Hammerschlag R, et al. Glob Adv Integr Med Health. 2024 Jan 31;13:27536130231202501. doi: 10.1177/27536130231202501. eCollection 2024 Jan-Dec. Glob Adv Integr Med Health. 2024. PMID: 38304734 Free PMC article. - Biofield Therapies: Guidelines for Reporting Clinical Trials.
Hammerschlag R, Sprengel M, Baldwin AL. Hammerschlag R, et al. J Integr Complement Med. 2024 Feb;30(2):133-145. doi: 10.1089/jicm.2024.29128.rh. Epub 2024 Feb 1. J Integr Complement Med. 2024. PMID: 38300148
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources